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Tissue acidosis does not mediate 
the hypoxia selectivity of [64Cu]
[Cu(ATSM)] in the isolated perfused 
rat heart
Friedrich Baark1,2, Fiona Shaughnessy1, Victoria R. Pell1,2, James E. Clark2, Thomas R. Eykyn1, 
Philip Blower1 & Richard Southworth  1
Copper-64-Diacetyl-bis(N4-methylthiosemicarbazone) [64Cu][Cu(ATSM)] is a hypoxia-targeting PET 
tracer with applications in oncology and cardiology. Upon entering a hypoxic cell, [64Cu][Cu(II)(ATSM)] 
is reduced to a putative [64Cu][Cu(I)(ATSM)]− species which dissociates to deposit radiocopper, thereby 
providing hypoxic contrast. This process may be dependent upon protonation arising from intracellular 
acidosis. Since acidosis is a hallmark of ischemic tissue and tumors, the hypoxia specificity of [64Cu]
[Cu(ATSM)] may be confounded by changes in intracellular pH. We have therefore determined the 
influence of intracellular pH on [64Cu][Cu(ATSM)] pharmacokinetics. Using isolated perfused rat hearts, 
acidosis was induced using an ammonium pre-pulse method, with and without hypoxic buffer perfusion. 
Cardiac [64Cu][Cu(ATSM)] pharmacokinetics were determined using NaI detectors, with intracellular pH 
and cardiac energetics monitored in parallel by 31P NMR. To distinguish direct acidotic effects on tracer 
pharmacokinetics from acidosis-induced hypocontractility, parallel studies used lidocaine perfusion to 
abolish cardiac contraction. Hypoxic myocardium trapped [64Cu][Cu(ATSM)] despite no evidence of it 
being acidotic when characterised by 31P NMR. Independent induction of tissue acidosis had no direct 
effect on [64Cu][Cu(ATSM)] pharmacokinetics in either normoxic or hypoxic hearts, beyond decreasing 
cardiac oxygen consumption to alleviate hypoxia and decrease tracer retention, leading us to conclude 
that tissue acidosis does not mediate the hypoxia selectivity of [64Cu][Cu(ATSM)].
Myocardial hypoxia is a major factor in the pathology of cardiac ischaemia, and has been implicated in the pro-
gression of numerous events associated with myocardial infarction and heart failure1–4, microvascular disease 
and cardiac hypertrophy5,6. Hypoxia is also a well-established characteristic of many cancers, induced by a cha-
otic vascular architecture which leads to both poor perfusion and decreased oxygen delivery, which frequently 
combine to limit the effectiveness of chemotherapy and radiotherapy7. The non-invasive quantification of tissue 
hypoxia by molecular imaging is therefore an attractive prospect for disease diagnosis, stratification, and predict-
ing or determining response to therapy in both cancer and cardiovascular disease8,9.
Radiolabeled Copper-bis(thiosemicarbazones) [64Cu][Cu(BTSCs)] are a family of hypoxia-avid positron 
emission tomography (PET) tracers which have been extensively investigated for applications in both oncology 
and cardiovascular medicine10–12. Copper-64-Diacetyl-bis(N4-methylthiosemicarbazone) [64Cu][Cu(ATSM)] is 
the current lead member of the class, which has been demonstrated to delineate hypoxic tissue in tumors10,13 and 
myocardium14,15 pre-clinically and clinically. While their sensitivity to tissue hypoxia is well-established, the exact 
mechanism of how this class of complexes deliver hypoxia-dependent contrast remains somewhat unclear16. As 
neutral lipophilic molecules, it is thought that they passively diffuse into and out of cells in their oxidized state. 
Under hypoxic conditions, they are reduced from copper (II) to an unstable copper (I) species9 which dissoci-
ates, releasing their radiocopper core to become trapped inside the cell, thereby providing hypoxia-dependent 
imaging contrast17 (Fig. 1). While it is not controversial that hypoxia promotes tissue radiocopper retention from 
these complexes, the intracellular interactions responsible for their reduction remain unidentified18. One ele-
ment which could affect this process either directly or indirectly is intracellular pH. Ligand protonation due to 
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acidosis may alter the redox potential of the oxidised Copper (II) species, thereby altering the lipophilicity of the 
reduced Copper (I) species, or the dissociation kinetics of the complex19. In vitro UV-Vis spectroscopy studies 
have demonstrated that the stability of various [64Cu][Cu(BTSCs)], such as PTSM and KTS complexes and their 
reduction products decrease substantially with reduced pH11,19, making them more prone to dissociation, while 
cyclic voltammetry suggests that [64Cu][Cu(ATSM)] is more readily reduced in acidic conditions19.
Ischemic myocardium and the tumour microenvironment are both potentially associated with acidosis. In 
myocardium, the net hydrolysis of ATP during ischemia leads to an increase in intracellular H+ concentration20, 
which has been demonstrated by 31P NMR spectroscopy to be more severe than that caused by hypoxia alone21. 
Commonly associated with hypoxia, acidosis is also a hallmark of aggressive tumors, driven by a glycolytic phe-
notype, the increased production and extrusion of H+ and lactate, and limited perfusion22. The importance of aci-
dosis is of increasing interest as a driver of tumor progression and metastatic spread22. If the hypoxia sensitivity of 
the [64Cu][Cu(BTSC)] complexes is mediated by (or heavily modified by) changes in intracellular or intra-tissue 
pH, this would greatly complicate the use and interpretation of the imaging data that they provide. While in vitro 
studies and in silico modeling19 suggest that pH may influence the hypoxia selectivity of these complexes, the issue 
has not yet been specifically investigated in a biologically relevant model of tissue hypoxia.
We have established an isolated perfused heart system coupled with a triple NaI gamma detection apparatus 
which allows the characterization of radiotracer pharmacokinetics in an intact functioning organ over which we 
have complete functional control15,23. Interventions can be performed accurately and reproducibly without the 
added complications of circulating tracer metabolites, under conditions which may otherwise be lethal in vivo. 
In this study, we have used this approach to investigate the interplay between tissue hypoxia and intracellular pH, 
independently and in combination, on radiotracer kinetics to establish whether tissue acidosis is fundamental to, 
or impacts upon, the hypoxia selectivity of [64Cu][Cu(ATSM)].
Results
Cardiac hemodynamics. Cardiac hemodynamic parameters from hearts across all treatment groups 
are shown in Fig. 2. Hypoxia invoked a rapid decrease in left ventricular developed pressure (LVDP), falling 
from 115.4 ± 13.4 to 35.5 ± 12.5 mmHg, with left ventricular end-diastolic pressure (LVEDP) increasing from 
7.5 ± 3.4 to 35.2 ± 12.9 mm, associated with a slight increase in coronary perfusion pressure (PP) from 93.4 ± 9.2 
Figure 1. (left) Structure of [Cu(ATSM)], (right) Generalised schematic of the proposed trapping mechanisms for 
[64Cu][Cu(BTSC)] PET tracers. [64Cu][Cu(II)(BTSCs)] passively diffuse into cells where they can be reduced to 
a charged Cu(I) complex which is unable to leave the cell. In the presence of oxygen this Cu(I) complex is rapidly 
reoxidised back to Cu(II) which is again able to diffuse out of the cell. If oxygen is insufficient, the Cu(I) complex 
can become further reduced and dissociate. The Cu(I) then becomes sequestered by copper chelating proteins and 
trapped inside the cell (Adapted with permission from Pell et al. 2018 under a CC BY open access licence)42.
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to 101.7 ± 15.6 mmHg. Ammonium prepulse-induced intracellular acidosis invoked a rapid reduction in LVDP 
from 90.7 ± 21.9 to 22.5 ± 11.1 mmHg within 5 mins in normoxic hearts, coupled with an increase in LVEDP 
in from 16.4 ± 5.3 to 38.2 ± 24.8 mmHg after 25 mins, with an increase in PP from 90.5 ± 10.00 mmHg to 
131.1 ± 25.2 mmHg. Washout of NH4Cl caused a further decrease to LVDP 5.5 ± 4.7 mmHg within 1 minute. 
After zoniporide washout, LVDP returned to 67.2 ± 15.2 mmHg. The functional effects of acidosis and hypoxia 
combined were not significantly different from those of acidosis alone, although the complete cessation of cardiac 
contraction caused by acidosis was more severe than the hypocontractile effect induced by hypoxic buffer perfu-
sion hypoxia alone. Infusion of 0.8 mM lidocaine induced comparable changes in cardiac function to those of the 
acidosis protocols. In both normoxic and hypoxic hearts, lidocaine abolished LVDP from 125.6 ± 6.1 to 0.54 ± 0.2 
Figure 2. Langendorff hemodynamic data showing changes in perfusion pressure, left ventricular developed 
pressure and left ventricular end-diastolic pressure from all treatment groups. Data are expressed as mean +/− 
SD (n = 5).
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and 139.7 ± 7.9 to 0.47 ± 0.13 respectively, returning to 123.7 ± 13.2 and 125.7 ± 14.06 after washout. LVEDP was 
increased with the addition of lidocaine from 3.5 ± 0.2 to 50.2 ± 14.02 in normoxic hearts and from 6.7 ± 0.68 
to 62.36 ± 20.3 in hypoxic hearts. Both of which returned close to pre-infusion values after lidocaine washout.
31P NMR spectroscopy. Figure 3 displays representative 31P NMR spectra and average pHi from (A) hearts 
subjected to hypoxia (20% O2) and (B) hypoxia + acidosis, to assess changes in cardiac energetics and myocar-
dial pHi. Hypoxia with 20% O2 did not affect pHi, which averaged between 7.13 ± 0.11 and 7.22 ± 0.1 and did 
not differ from time-matched normoxic control pHi. Perfusion with 20% O2 KHB plus NH4Cl and zoniporide 
caused pHi to decrease from 7.1 ± 0.07 to 6.4 ± 0.06 (p < 0.05), returning to 7.1 ± 0.10 (which was comparable to 
time-matched normoxic controls) 15 minutes after zoniporide washout.
Cardiac lactate release. Lactate release from hearts in all treatment groups are summarized in Fig. 4. 
Lactate release from normoxic control hearts was minimal during normoxic perfusion (0.085 ± 0.01 to 
0.011 ± 0.03 mmol/L). Perfusion with hypoxic buffer caused elevated lactate washout, reaching a maximum of 
0.35 ± 0.03 mmol/L after 20 mins of hypoxia. In normoxic hearts, perfusion with NH4Cl caused a transient but 
not significant small increase in lactate release from 0.10 ± 0.03 to 0.15 ± 0.11 mmol/L within 2 minutes which 
decreased again upon NH4Cl washout. Lactate release from acidotic hearts perfused with hypoxic buffer did not 
increase throughout the protocol and were not significantly different from non-acidotic control hearts. Lidocaine 
infusion abolished lactate release during normoxic buffer perfusion, which was not significantly different from 
the low lactate washout observed in the acidotic group, but significantly lower than that observed in the hypoxia 
alone perfusion group (p < 0.05).
Cardiac Copper-64 retention. Representative traces from the Na/I detector interrogating the heart dur-
ing examples of each perfusion protocol are shown in Fig. 5, and summarized across all hearts in Fig. 6. During 
normoxic perfusion, 10.1% ± 2.5% of the injected dose (ID) was retained in the heart 20 min after the first injec-
tion, and this level of radiotracer retention was consistently observed in the subsequent injections in the nor-
moxic control heart. Induction of acidosis in normoxic hearts caused a decrease in cardiac Copper-64 retention 
from 9.3% ± 2.7% during the control period to 2.4% ± 1.6% (p < 0.05), returning to 12.7% ± 3.0% 15 mins after 
zoniporide/acid washout. Perfusion with hypoxic buffer caused a significant increase in tracer retention from 
11.0% ± 2.2% to 46.5% ± 12.0% ID (p < 0.05). However, inducing acidosis in hypoxic hearts abolished Copper-64 
retention such that it was not significantly different to pre-hypoxic values. Lidocaine infusion in normoxic hearts 
had a similar effect to acidosis, with Copper-64 retention falling from 9.22% ± 0.79% to 4.93% ± 0.8% (p < 0.05) 
before returning to pre-lidocaine values (10.7% ± 0.6% ID). Lidocaine infusion also abolished the elevated 
Copper-64 retention previously seen in hypoxic hearts.
Figure 3. (A) Representative stacked plot of 31P NMR spectra acquired from a hypoxic control (20% O2) heart 
along with single spectra stacked plot and myocardial pHi. (B) Representative stacked plot of 31P NMR spectra 
acquired from a hypoxic (20% O2) acidotic heart along with single spectra stacked plot and myocardial pHi 
(data are expressed as mean ± standard deviation, n = 5).
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Discussion
In this study we show that, contrary to prior suggestions based on in vitro physicochemical and electrochemical 
studies and in silico calculations, acidosis is not a significant mechanism for the trapping of [64Cu][Cu(ATSM)] 
in hypoxic tissues ex vivo. We demonstrate significant cardiac retention of [64Cu][Cu(ATSM)] in myocardium 
perfused with hypoxic buffer, which exhibits no measurable intracellular acidosis when measured by 31P NMR 
spectroscopy. Acidosis can therefore not be a prime determinant of tissue [64Cu][Cu(ATSM)] retention. While 
acidosis is a well characterized phenomenon in ischemic hearts, and has been robustly demonstrated by 31P 
NMR ex vivo and in vivo by ourselves and many others24–26, maintaining coronary flow constant to specifically 
induce hypoxia (which our model allows) washes protons arising from net ATP hydrolysis from the myocardium 
sufficiently rapidly that they do not cause measurable tissue acidosis. Thus, our model allows us to specifically 
demonstrate the hypoxia-dependent tissue accumulation of [64Cu][Cu(ATSM)] without the confounding effects 
of changes in perfusion which often complicate such studies in cancer models, and to confirm the lack of cor-
relation between acidosis and [64Cu][Cu(ATSM)] retention. We show that surprisingly, rather than promoting 
[64Cu][Cu(ATSM)] dissociation and Copper-64 retention as might be predicted, when invoked pharmacolog-
ically either in the presence or absence of hypoxia, acidosis indirectly decreases [64Cu][Cu(ATSM)] retention 
in our experimental model by lowering cardiac oxygen consumption via the inhibition of cardiac contraction. 
We mimicked this condition by inhibiting cardiac contraction by lidocaine infusion to achieve the same effect, 
such that tissues were no longer sufficiently hypoxic to retain [64Cu][Cu(ATSM)], despite being perfused with 
hypoxic buffer. We demonstrate the oxygen-salving effect of this mechanical unloading by the normalization of 
cardiac energetics (by 31P NMR spectroscopy), and the abolition of lactate washout from hypoxic hearts (which 
reflects a return from anaerobic to aerobic glycolysis) when either simultaneously made acidotic, or perfused with 
lidocaine. As we have previously demonstrated, [64Cu][Cu(ATSM)] exhibits a sigmoidal relationship between 
tissue oxygenation and tracer retention, and is selective for relatively extreme degrees of hypoxia27; by lowering 
oxygen demand in our hearts, we conclude that we have indirectly raised intracardiac oxygen saturation to above 
the threshold necessary for tissue [64Cu][Cu(ATSM)] retention. This oxygen-sparing effect is also observable 
Figure 4. Cardiac lactate release. Lactate concentration was measured in perfusate samples collected from 
isolated perfused hearts. Data are expressed as means ± SD (n = 5).
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in acidotic hearts during normoxic perfusion, where baseline [64Cu][Cu(ATSM)] retention was lower than in 
untreated normoxic control hearts. While the Langendorff isolated perfused heart is energetically stable for sev-
eral hours, it is potentially at the brink of normoxia because KHB has a lower oxygen-carrying capacity than 
blood, even when saturated with 95% O2/5% CO2. This is apparent from the significant vasodilation and high cor-
onary flows associated with crystalloid versus blood perfused preparations28. Isolated hearts perfused with KHB 
are almost maximally vasodilated, which has led to the suggestion that they may be slightly hypoxic, particu-
larly in the endocardium, where energy (and oxygen) demands are highest29. While in previous studies we had 
attributed the baseline level of [64Cu][Cu(ATSM)] cardiac retention in “normoxically-perfused” isolated hearts 
to be due to non-specific retention in cell membranes (due to their lipophilicity), our data suggest that some of 
this retention may represent a small fraction of hypoxic cells within a crystalloid-perfused heart, which become 
normoxic once when the heart is mechanically unloaded. We have recently shown by 31P NMR that mechanically 
uncoupling isolated hearts with blebbistatin elevates both phosphocreatine levels and ATP content in “normoxic” 
crystalloid buffer-perfused isolated hearts which would be consistent with this30.
We exploited the ammonium prepulse approach to specifically induce intracellular acidosis, as opposed to 
perfusing with acidotic buffers, which would not necessarily translate to intracellular acidosis. This also allowed 
us to exclude the possibility of protonation of the complex by acidotic buffer before it reached the heart in our 
study. The ammonium prepulse approach coupled with NHE inhibition is an established means of inducing and 
maintaining intracellular acidosis in both basic cardiac research and other applications31,32; similar, but less severe 
intracellular acidosis of pH 6.7 has previously been demonstrated with a similar protocol in isolated perfused 
ferret hearts using the NHE inhibitor 5-(N-ethyl-N-isopropyl)amiloride (EIPA)33, while similar effects on con-
tractile function to those we report here have previously been demonstrated with NH4Cl infusion and NHE-1 
inhibitor cariporide34. While NHE inhibition is associated with a loss of Ca2+ uptake via NCX, acidosis-mediated 
Figure 5. Representative time-activity curves demonstrating Copper-64 retention from [64Cu][Cu(ATSM)] 
across all treatment groups.
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loss of contractile function is not due to the decrease in Ca2+ concentration, but to a decrease in contractile 
protein responsiveness to Ca2+ 35. We demonstrate that zoniporide treatment alone had no effect on Copper-64 
retention during normoxia or hypoxia compared to vehicle control, which confirms that there was no interaction 
between zoniporide and [64Cu][Cu(ATSM)] which may have affected myocardial uptake or dissociation.
Conclusion
Radiocopper bis(thiosemicarbazone) complexes represent a versatile family of hypoxia imaging agents with a 
range of hypoxia selectivities for a variety of applications in both cardiology and oncology. To optimize the diag-
nostic and prognostic insight gained from the PET images with these complexes, it is essential to understand the 
nature of their tissue uptake and retention. Here, we demonstrate that their hypoxia-dependent tissue retention 
is not dependent upon intracellular acidosis (nor indeed directly affected by it) and confirm their specificity to 
changes in intracellular oxygen saturation.
Materials and Methods
Reagents and gas mixtures. All reagents were purchased from Sigma Aldrich (Poole, Dorset, UK) unless 
otherwise stated. All gas mixtures were purchased from BOC, UK. Specialist gas mixtures were certified by the 
manufacturer.
[64Cu][Cu(ATSM)] production. Copper-64 was provided by the PET Imaging Centre, St. Thomas’ Hospital, 
London. ATSM was labeled with Copper-64 as described by Handley et al.36.
Animals. Male Wistar rats (250 to 300 g: Charles River) with ad libitum access to food and water were used 
throughout. All experimental procedures were approved by King’s College London’s local Animal Care and Ethics 
Committee, and carried out in accordance with Home Office regulations as detailed in the Guidance on the 
Operation of Animals (Scientific Procedures) Act 1986.
Figure 6. Tissue retention of [64Cu][Cu(ATSM)] (% of injected dose) across all treatment groups. Data are 
expressed as mean ± SD. (n = 5).
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Heart perfusion protocol. Rats were anesthetised with sodium pentobarbitone and heparinised (200 
IU intraperitoneal). Hearts were excised and placed immediately in Krebs-Henseleit Buffer (KHB) at 4 °C, 
comprising NaCl (118 mmol/L), KCl (5.9 mmol/L), MgSO4 (1.16 mmol/L), NaHCO3 (25 mmol/L), NaEDTA 
(0.48 mmol/L), glucose (11.1 mmol/L) and CaCl2 (2.2 mmol/L) prior to Langendorff perfusion at a constant rate 
of 14 mL/min with KHB gassed with 95%O2/5%CO2 at 37 °C, as we have described previously12,37. Hypoxia was 
induced by switching to KHB equilibrated with 20%O2/75%N2/5%CO2. Buffer oxygen saturation was monitored 
throughout each experiment by an OxyLite™ fluorescent oxygen probe (Oxford Optronix Ltd., Oxfordshire, UK) 
inserted into the arterial perfusion line. Coronary perfusion pressure was monitored via a pressure transducer 
mounted in the arterial line. Cardiac contractile function was monitored via a pressure transducer connected 
to a latex balloon inserted into the left ventricle, inflated to an end-diastolic pressure of 4 to 9 mmHg. All hearts 
were perfused with normoxic KHB for a stabilization period of 10 min to ensure contractile function exclusion 
criteria were met before continuing each experiment. Hearts were then perfused for a further 45 min according 
to the protocol schematics in Fig. 7. In each experiment, three boluses of [64Cu][Cu(ATSM)] (2 MBq in 100 μL 
KHB) were injected into the arterial perfusion line at the end of the stabilization period (to obtain a baseline 
measurement), 20 minutes after the induction of each intervention, and 15 minutes after the cessation of each 
intervention. An ammonium pre-pulse technique was employed to induce intracellular acidosis38, which was 
maintained by infusion of the sodium hydrogen exchanger (NHE-1) inhibitor zoniporide39 in bicarbonate free 
buffer (to limit buffering capacity). Hypoxia was induced by perfusing hearts with KHB gassed with 20% O2. 
Since tissue acidosis inhibits cardiac contractility, which would potentially have an oxygen-salving effect which 
may itself affect hypoxia tracer pharmacokinetics, we perfused further groups of hearts with 0.8 mM lidocaine 
to inhibit cardiac contractility to establish the effect of tissue hypocontractility on tracer pharmacokinetics inde-
pendent of intracellular pH.
31P MR Spectroscopic Analysis. Changes in cardiac energetics and intracellular pH were monitored in 
real time in parallel groups of hearts using 31P NMR spectroscopy. Hearts were cannulated and perfused with 
KHB in Langendorff mode and inserted into a 15 mm glass MR tube, which was inserted into a custom-built 
MR spectroscopy probe, as previously described40. 31P NMR spectra were acquired on an Bruker Avance III 9.4 T 
spectrometer using a 15 mm 31P/1H birdcage coil41. Shimming was performed on the 1H line shape of water (full 
width at half maximum <20 Hz). 31P spectra were acquired with a pulse-acquire sequence using a 60° flip angle, 
a repetition time of 3.8 s, and 64 scans (4 min per spectrum). The peak area of each metabolite was normalized to 
that of phosphocreatine during normoxia.
Lactate measurement. 0.5 mL of coronary effluent was collected at regular intervals during perfusion and 
analyzed for lactate content to identify the onset of anaerobic glycolysis using a 2300 STAT Plus lactate analyzer 
(YSI Ltd) as described previously37.
Radiometric measurement. Cardiac radiotracer injection, retention and washout was monitored through-
out using three orthogonally-arranged lead-collimated Na/I γ-radiation detectors (Raytest Isotopenmessgeräte 
GmbH, Straubenhardt, Germany) measuring Copper-64 activity at the input (arterial) perfusion line, the heart 
and the output perfusion line respectively. The detectors were connected to a Gina Star™ data acquisition system 
Figure 7. Perfusion protocols for hearts from all treatment groups. (A) Normoxic control, (B) 
Normoxia + acidosis (C) Hypoxic control (D) Hypoxia + acidosis (E) Normoxia + lidocaine infusion (F) 
Hypoxia + lidocaine infusion.
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(Raytest Isotopenmessgeräte GmbH) as previously described15. Data were normalized to the maximum peak 
counts after each injection and corrected for decay and cardiac background activity 30 seconds prior to each 
injection.
Statistical analysis. All data are presented as mean ± standard deviation. Statistical significance was calcu-
lated using a one-way ANOVA followed by Bonferroni post hoc test, or Dunnett test when multiple comparisons 
were made to a control group, using GraphPad Prism (GraphPad software Inc., San Diego, CA, USA).
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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